Future studies are suggested to involve establishing the criteria for assessing treatment response in RA patients using DAS28-MCP-1 and confirming X-ray changes related to changes in DAS28-MCP-1 scores. This evidence concerns the gene CCL2 and rheumatoid arthritis.